Company Filing History:
Years Active: 2015
Title: Johan Bylund – Innovator in Therapeutic Compounds
Introduction
Johan Bylund is a notable inventor based in Södertälje, Sweden, recognized for his groundbreaking contributions to the field of pharmaceuticals. With a focus on developing novel therapeutic compounds, Bylund's work exemplifies the intersection of innovation and healthcare.
Latest Patents
Bylund holds a significant patent titled "Bis-(sulfonylamino) derivatives for use in therapy." This invention provides compounds of a specific formula, which includes optical isomers, racemates, tautomers, and pharmaceutically acceptable salts. These compounds serve as inhibitors of microsomal prostaglandin E synthase-1 and have potential applications in therapeutic treatments. The patent outlines not only the compounds but also processes for their preparation and their use in pharmaceutical compositions.
Career Highlights
Currently, Johan Bylund is affiliated with AstraZeneca AB, a leading global biopharmaceutical company. His role as an inventor highlights his commitment to advancing medical science and improving patient outcomes through innovative drug development.
Collaborations
Throughout his career, Bylund has collaborated with distinguished colleagues, including Maria E Ek and Ylva Gravenfors. These collaborations underscore the importance of teamwork and shared expertise in the pursuit of groundbreaking innovations in the pharmaceutical industry.
Conclusion
Johan Bylund's contributions to the field of therapeutic compounds reflect his dedication as an inventor. His patent for bis-(sulfonylamino) derivatives marks a significant advancement in therapy, showcasing the potential of his work to impact medical treatments positively. As part of AstraZeneca AB, Bylund continues to be an influential figure in the realm of pharmaceutical innovation, paving the way for future advancements.